Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR39 | O43194 | 10/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3716806 | 0.90 | FYN (0.34) | CDK9HRH4ALDH1A1SMN1; SMN2HRH1 | |
| SCHEMBL3726295 | 0.89 | ACHE (0.42) | GPR39GRM5ACHEPPP1CASMN1; SMN2 | |
| SCHEMBL3723915 | 0.87 | CYP1A2 (0.36) | GPR39GRM5CYP1A2CYP2D6 | |
| SCHEMBL3723884 | 0.79 | ACHE (0.38) | ACHEHRH4ALDH1A1SMN1; SMN2HRH1 | |
| SCHEMBL3720880 | 0.75 | GPR39 (0.38) | GPR39GRM5CYP2D6 | |
| SCHEMBL3721182 | 0.74 | GRM5 (0.36) | GRM5CYP2D6 | |
| SCHEMBL3664081 | 0.73 | GPR39 (0.49) | GPR39ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3727474 | 0.73 | GPR39 (0.47) | GPR39ACHECDK9 | |
| SCHEMBL3722419 | 0.73 | GPR39 (0.48) | GPR39ACHE | |
| SCHEMBL3662804 | 0.72 | CYP3A4 (0.58) | GPR39ALDH1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | GPR39 222/4885F2 301/4885GRM5 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.